Associations - BRAF V600K

BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
BRAF V600K	Melanoma	BRAF V600K	Melanoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
BRAF V600K	Melanoma	BRAF V600K	Melanoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
BRAF V600K	Melanoma	BRAF V600K	Melanoma	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B	encorafenib Sensitive: B - Late Trials encorafenib Sensitive : B
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	trametinib Sensitive: C1 - Off-label trametinib Sensitive : C1	trametinib Sensitive: C1 - Off-label trametinib Sensitive : C1
BRAF V600K	Solid Tumor	BRAF V600K	Solid Tumor	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria pembrolizumab + trametinib + dabrafenib Sensitive : C2	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria pembrolizumab + trametinib + dabrafenib Sensitive : C2
BRAF V600K	Melanoma	BRAF V600K	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: C2 – Inclusion Criteria atezolizumab + vemurafenib + cobimetinib Sensitive : C2	atezolizumab + vemurafenib + cobimetinib Sensitive: C2 – Inclusion Criteria atezolizumab + vemurafenib + cobimetinib Sensitive : C2
BRAF V600K	Solid Tumor	BRAF V600K	Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF V600K	Melanoma	BRAF V600K	Melanoma	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF V600K	Melanoma	BRAF V600K	Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
BRAF V600K	Melanoma	BRAF V600K	Melanoma	9-ING-41 Sensitive: C3 – Early Trials 9-ING-41 Sensitive : C3	9-ING-41 Sensitive: C3 – Early Trials 9-ING-41 Sensitive : C3
BRAF V600K	Melanoma	BRAF V600K	Melanoma	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : C3	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor + CTLA4 inhibitor Sensitive : C3
BRAF V600K	Melanoma	BRAF V600K	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BRAF V600K	Melanoma	BRAF V600K	Melanoma	pembrolizumab + vemurafenib + cobimetinib Sensitive: C3 – Early Trials pembrolizumab + vemurafenib + cobimetinib Sensitive : C3	pembrolizumab + vemurafenib + cobimetinib Sensitive: C3 – Early Trials pembrolizumab + vemurafenib + cobimetinib Sensitive : C3
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib + MCS110 Sensitive: C3 – Early Trials trametinib + dabrafenib + MCS110 Sensitive : C3	trametinib + dabrafenib + MCS110 Sensitive: C3 – Early Trials trametinib + dabrafenib + MCS110 Sensitive : C3